

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over ID1523

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Emmaus Medical (L-glutamine) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Black Health Agency • Contact a Family • Equalities National Council • Genetic Alliance UK • Muslim Council of Britain • National Children's Bureau • Pain UK • Sickle Cell Society • South Asian Health Foundation • Specialised Healthcare Alliance • The UK Thalassaemia Society <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses & Counsellors • British Committee for Standards in Haematology • British Geriatrics Society • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Haematology • British Society for Human Genetics • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible Comparator companies</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb (hydroxycarbamide) • Medac GmbH (hydroxycarbamide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Cystic Fibrosis & Genetic Disorders Group • Cochrane Haematological Malignancies Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research

© National Institute for Health and Care Excellence 2019. All rights reserved

Provisional Matrix for the proposed technology appraisal of l-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over ID1523

Issue date: January 2019

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Forum on Haemoglobin Disorders • UK Genetic Testing Network • United Kingdom National Screening Committee <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Halton CCG • NHS Lewisham CCG • Welsh Government 	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.